OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
54 hedge funds and large institutions have $40.2M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 17 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
9% less capital invested
Capital invested by funds: $44.4M → $40.2M (-$4.13M)
14% less funds holding
Funds holding: 63 → 54 (-9)
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$1.52M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$525K |
| 3 |
BC
Broadfin Capital
New York
|
+$479K |
| 4 |
Primecap Management
Pasadena,
California
|
+$323K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$231K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.23M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$654K |
| 3 |
First Eagle Investment Management
New York
|
-$507K |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$483K |
| 5 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$351K |
OMED Hedge Fund Activity: Q3 2018 in Review
54 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2018, worth a combined $40.2M — down 9.3% from $44.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of OMED and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 17 added.
The largest buyer was Nexthera Capital, opening a new position worth an estimated $1.52M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.23M sold.
- 54 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2018, down from 63 in Q2 2018.
- Funds reported $40.2M of OncoMed Pharmaceuticals, Inc. stock for Q3 2018, down 9.3% quarter-over-quarter.
- 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2018 and 17 closed out, a net change of -9 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2018 was Nexthera Capital, an estimated $1.52M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2018 was Alyeska Investment Group, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2018.